# Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19

> **NCT04382066** · PHASE1 · COMPLETED · sponsor: **PharmaMar** · enrollment: 46 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Plitidepsin 1.5 mg/day
- **DRUG:** Plitidepsin 2.0 mg/day
- **DRUG:** Plitidepsin 2.5 mg/day

## Key facts

- **NCT ID:** NCT04382066
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-12
- **Primary completion:** 2020-11-26
- **Final completion:** 2020-11-26
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382066, "Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04382066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*